Objective; To study the Fuzheng Quxie drink and telbivudine combination therapy for chronic hepatitis B, and observe the key indicators of HBeAg seroconversion. Methods; Fuzheng Quxie drink and telbivudine were applicated the combined group , the drink was taken each morning and evening, each oral 150ml, for 6 months; telbivudine tablets taken once a day, each one (600mg), for 12 months; the control group was with telbivudine, usage, and the same treatment with the combination group. Clinical improvement , liver function, HBV DNA, HBeAg negative and HBeAg/anti-Hbe seroconversion were observed after treatment Results: ALT, AST, Tbil, HBeAg seroconversion rate, HBeAg/anti-Hbe seroconversion, HBV DNA negative rate after treatment, compared with before treatment were significant (P <0. 01 orP <0. 05) ; Comparing the effect of the two groups after treatment, the combined group in ALT levels, HBeAg seroconversion rate, HBeAg / anti-Hbe seroconversion rate was better than the control group in the early response (P<0. 05) , but the difference was not statistically significant (P> 0. 05 ) . Conclusion: Fuzheng Quxie drink joint telbivudine tablets has significant effect in the treatment of chronic hepatitis B, Fuzhenquxie drink can promote the recovery of liver function, promote HBeAg loss and HBeAg / anti-Hbe seroconversion response in advance, and can be used as the adjuvant treatment of chronic hepatitis B.%目的:探讨扶正祛邪饮与替比夫定联合治疗慢性乙型肝炎的疗效,重点观察HBeAg血清转换指标.方法:96例患者按意愿分为联合组50例和对照组46例,联合组患者口服替比夫定片,1次/d,600mg/次,疗程12个月.另加服扶正祛邪饮,2次/d,150ml/次,疗程6个月；对照组患者单用替比夫定,用法和疗程与联合组相同.观察两组患者治疗前后的临床症状改善、肝功能好转、HBV DNA下降、HBeAg转阴及HBeAg/抗-HBe血清转换的效果.结果:两组患者治疗后的ALT、AST、TBil、HBeAg转阴率、HBeAg/抗-HBe血清转换率、HBV DNA转阴率,与治疗前比较差异有显著性意义(P ＜0.01或P＜0.05)；两组患者治疗后的比较,联合组在ALT水平、HBeAg转阴率、HBeAg/抗-HBe血清转换率等早期应答方面优于对照组(P＜0.05),联合组HBeAg转阴率、HBeAg/抗-HBe血清转换率在治疗12月时高于对照组,但差异无统计学意义(P＞0.05).结论:扶正祛邪饮联合替比夫定片治疗慢性乙型肝炎早期疗效明显,肝功能恢复较快,且能促进HBeAg转阴和HBeAg/抗-HBe血清转换提前应答,可作为慢性乙型肝炎治疗的辅助药物.
展开▼
